Production of a dual-species Bose-Einstein condensate of Rb and Cs atoms

We report the simultaneous production of Bose-Einstein condensates (BECs) of $^{87}$Rb and $^{133}$Cs atoms in separate optical traps. The two samples are mixed during laser cooling and loading but are separated by $400 \mu$m for the final stage of evaporative cooling. This is done to avoid considerable interspecies three-body recombination, which causes heating and evaporative loss. We characterize the BEC production process, discuss limitations, and outline the use of the dual-species BEC in future experiments to produce rovibronic ground state molecules, including a scheme facilitated by the superfluid-to-Mott-insulator (SF-MI) phase transition

Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia:a Multinational Point Prevalence Study of Hospitalised Patients

Pseudornonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients